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Prostate cancer (PCa) is one of the leading causes of cancer death among males, especially in
5 more developed countries. Diagnosis is often achieved at an early stage of the disease with
prostate biopsy, following a screening test showing elevated serum levels of prostate-specific
antigen or a positive digital rectal examination. Early detection of PCa has led to a substantial
decline in the number of metastatic patients. However, the prostate-specific antigen screening
test has proved to be a double-edged sword so far, as it also accounts for PCa overdiagnosis.
10 Due to the variability of PCa features, accurate prognosis of PCa patients is very important for
determining treatment options. Therefore, this review focuses on the most promising prog-
nostic and predictive biomarkers in PCa, which are likely to play a pivotal role, alone or in
panels, in the personalized medicine era that has recently emerged.
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Prostate cancer (PCa) is the most frequently
diagnosed cancer among men in developed
countries and the second most common world-
wide, after lung cancer. An estimated 1.1 mil-
20 lion new PCa cases and 307 thousand PCa
deaths occurred in 2012 worldwide.[1] PCa
can be a serious disease, but most men diag-
nosed with this malignancy do not succumb to
it. In fact, more than 2.9 million men in the
25 United States who have been diagnosed with
PCa at some point are still alive today. Relative
survival rates of PCa patients are high, mostly
due to early diagnosis based on the measure-
ment of prostate-specific antigen (PSA) and to
30 slow progression of the disease in many
cases.[2]
Besides for diagnostic purposes, the PSA test
is also used to monitor surgically treated PCa
patients for disease recurrence. Thus, patients
35 with a history of PCa and elevated PSA levels
are considered to have a biochemical relapse,
which typically appears months or years before
other clinical signs and symptoms of PCa
recurrence. Nevertheless, a single increased
40 PSA value in a patient who has a history of
PCa does not necessarily mean PCa relapse.
Moreover, no other molecular biomarkers are
used for PCa patient prognosis, monitoring or
prediction of patient response to therapy.[3]
45Staging is one of the most critical factors for
defining prognosis and for decision-making
with regard to PCa treatment options. PCa
staging is based on the prostate biopsy results
including the Gleason score, the PSA level and
50any other tests revealing how far PCa has
spread. The most widely applied staging system
for PCa is the TNM AQ1system of the American
Joint Committee on Cancer . Recently, how-
ever, an alternative staging process, called
55stage grouping, has been established; stage
grouping constitutes a combination of the
determined T, N, and M categories with the
Gleason score and PSA concentration.
Since there are many treatment options for
60men with PCa, it is important to have an
accurate prognosis. Nevertheless, the currently
used prognostic factors lead to overtreatment of
PCa, especially in men of 66 years and older
with a limited life expectancy. Thus, these men
65are likely to be aggressively treated, as age at
PCa diagnosis and comorbidities are not inte-
grated into patient prognosis and subsequent
treatment decision-making.
Many research efforts have been focused on
70the discovery of novel protein and genetic
biomarkers in order to refine prognostication
in PCa and predict the benefit derived from the
systemic treatment of PCa patients. This review
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summarizes current knowledge about promising prognostic and
75 predictive biomarkers in PCa, which can play a major role in the
personalized medicine era that has recently emerged.
Protein-coding genes as molecular biomarkers in PCa
Kallikrein-related peptidases 
Tissue kallikrein (KLK1) and kallikrein-related peptidases
80 (KLKs) are single-chain, secreted trypsin- or chymotrypsin-like
serine peptidases. KLKs are mainly produced and secreted by
epithelial cells composing the glandular epithelia of many
organs, including prostate, breast, colon, ovary, pancreas, brain 
and skin. Secreted KLKs enter body fluids such as sweat, milk,
85 saliva, seminal plasma, cerebrospinal fluid or remain in the
pericellular space.[4] KLKs are implicated in a great variety of
distinct physiological processes such as remodeling of the extra-
cellular matrix, prohormone processing, neural plasticity, skin
desquamation, regulation of blood pressure and electrolyte bal-
90 ance. Due to their ability to activate cell-surface receptors and
other proteases by proteolytic cleavage, KLKs participating in
proteolytic cascades, thus mediating signal transductionAQ2 .[5]
Although several in vivo targets of KLKs have already been
described, no prostate-specific substrates have been identi-
95 fied, yet.
Measurement of total PSA has been demonstrated to be
useful as a prognostic indicator, with high preoperative tPSAAQ3
values being associated with advanced stages of PCa, thus pre-
dicting a poor clinical outcome. In addition to PSA, several
100 other members of the KLK family (KLK2, KLK4, KLK5,
KLK11, KLK14 and KLK15) have been intensively studied for
their ability to assist PCa prognosis and/or therapy response
monitoring.[6] Perhaps the most important finding with regard
to prediction of risk of biochemical recurrence in men with
105 serum PSA values of ≤10 μg/L is the fact that total KLK2
concentration in serum provides improved and independent
prognostic information compared with PSA.[7] Artificial neural
networks combining tPSA, fPSAAQ4 /tPSA, KLK2, KLK2/fPSA and
KLK2/(fPSA/tPSA) as input variables have also been shown to
110 provide increased diagnostic and prognostic value for PCa.[8]
Moreover, high KLK4 mRNA levels are associated with
advanced PCa and strongly correlated with elevated tPSA con-
centration values measured in preoperative sera. The investiga-
tion of the prognostic potential of KLK5 and KLK11 mRNA
115 expression in needle biopsies from PCa patients led to the
conclusion that these two genes represent two promising, inde-
pendent prognostic biomarkers in PCa. Furthermore, KLK15
mRNA expression has also been suggested as a novel molecular
biomarker predicting treatment response in PCa cells. Specific
120 KLK15 transcripts were found to be aberrantly expressed in
more aggressive prostate tumors, thus implying an unfavorable
prognostic role for this gene in PCa.[6]
Androgen receptor 
The androgen receptor (AR) is a member of the nuclear receptor
125 superfamily that becomes activated when it binds either of the
androgenic hormones, testosterone or its metabolite,
dihydrotestosterone. After its activation, AR can translocate
from the cytoplasm into the nucleus and act as a transcription
factor, or exert its action directly in the cytoplasm, interacting
130with and activating the non receptor tyrosine kinase SRC.
Besides cytoplasmic AR, there is also a membrane-associated
AR isoform that, like cytoplasmic AR, potentiates proliferative
and survival responses in PCa cells.[9]
AR regulates the expression of genes involved in the prolif-
135eration and differentiation of PCa cells, not only by binding
with androgens in the epithelium but also in the prostate
stroma.[10] The loss of AR in the stroma surrounding the
malignant prostatic epithelium is supposed to exert a pivotal
role in PCa progression and to hold prognostic significance,
140especially among castration-resistant PCa patients. It has also
been suggested that the similarity of the loss of stromal AR
expression in newly diagnosed and hormone-resistant PCa
implies that the mechanisms accounting for the acquisition of
hormone independence are established early in the malignant
145transformation.[11] Profound alterations in AR expression in
the malignant epithelium and normal surrounding stroma are
inversely associated with Gleason score, distant metastasis,
tumor stage, response to castration therapy and biochemical
relapse.[11,12] Furthermore, AR was shown to mediate PCa
150recurrence after androgen deprivation therapy.[13]
In addition to AR protein levels, post-translational modifica-
tions of AR hold their own prognostic significance in PCa. For
instance, phosphorylation of AR at serine 213 is related to
inferior overall survival of patients with hormone-refractory
155PCa.[14] Similarly, phosphorylation of AR at serine 515 is a
predictor of shorter time to biochemical relapse.[15] On the
contrary, phosphorylation of AR at serine 308 and serine 791
was a favorable prognosticator in terms of overall survival of
patients with castrate-resistant PCa.[16]
160Secreted frizzled-related proteins 1 (SFRP1) and 2 (SFRP2)
Secreted frizzled-related protein 1 (SFRP1), also known as
SARP2, has been extensively studied in the past years for its
biological significance as well as its potential value as a prog-
nostic and/or predictive biomarker in PCa. SFRP1 is frequently
165downregulated in many types of cancer, including PCa.
Alterations of the expression balance between SFRP1 and β-
catenin plays a key role in both carcinogenesis and tumor
progression.[17]
SFRP1 counteracts WNT/β-catenin signaling by binding to
170the WNT proteins through its cysteine-rich domain, which is
homologous to the one of frizzled receptors. Loss of SFRP1 can
result in activation of WNT/β-catenin signaling.[18] WNT
proteins compose a major family of signaling molecules that
orchestrate and influence a myriad of cell biological and devel-
175opmental processes because of their participation in vital cellular
functions such as cell proliferation, migration, differentiation,
synaptic activity and embryogenesis. Moreover, SFRP1 has been
shown to mediate stromal-to-epithelial paracrine signaling in
PCa and is thus likely to account for the capacity of prostatic
180tumor stroma to provide a pro-proliferative paracrine signal to
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adjacent epithelial cells.[19] In fact, forced overexpression of
SFRP1 in prostatic epithelial cells did not modulate canonical
WNTAQ5 /beta-catenin signaling or activation of calcium/calmodu-
lin-dependent protein kinase II gamma (CAMK2G), but
185 resulted in sustained activation of JNK. Furthermore, blockage
of JNK activity inhibited the SFRP1-induced proliferation of
prostatic epithelial cells. Taken together, these data suggest that
SFRP1 acts through the non canonical WNT/JNKAQ6 pathway in
the prostate.[17] Besides compromising WNT/β-catenin signal-
190 ing, treatment of a human prostatic epithelial cell line with
SFRP1 led to enhanced cell proliferation and decreased apop-
tosis, in vitro.[19] On the other hand, loss of SFRP1 expression
has been reported in several distinct types of cancer, including
PCa.[20] In general, promoter CpG hypermethylation as well as
195 chromosomal deletions are the two main causes for dramatic
downregulation or loss of SFRP1 gene expression.[20,21]
Nevertheless, hypermethylation of SFRP1 is rare in PCa tis-
sues,[22] suggesting that chromosomal deletion may account
for the transcriptional silencing of SFRP1 in PCa.
200 A very recent study focusing on the prognostic and predictive
ability of SFRP1 has revealed that the expression levels of
SFRP1 and β-catenin are associated with the Gleason score,
survival rate and response of PCa patients to endocrine therapy.
Furthermore, mRNA and protein expression of the SFRP1 gene
205 was significantly higher in the androgen-dependent PCa cell line
-LNCaP than in the androgen-independent PCa cell lines DU
145 and PC-3. Therefore, SFRP1 expression, which inversely
correlates with the expression of β-catenin, appears to be a
favorable prognostic biomarker in PCa.[23] In accordance
210 with these findings, restoration of normal SFRP1 levels in PCa
cell lines treated with genistein – achieved through DNA
methylation or histone modifications – reduced their prolifera-
tion, invasion and migration potential.[24] Similarly, a combi-
nation of DNA demethylation and EZH2 inhibition managed
215 to trigger re-expression of the silenced tumor-suppressor SFRP1
gene and hence showed an additive inhibitory effect on growth
of PCa cells in vitro, rendering SFRP1 a promising target for
cancer cell-specific epigenetic therapy.[25]
Besides SFRP1,  14 other WNT/β-catenin signaling-related
220 genes were shown to have a significantly altered expression
profile in PCa. The majority of these genes were upregulated
in malignant prostate tumors, in contrast to SFRP1 and its
paralog, SFRP2. The observed downregulation of SFRP2 gene
expression was mainly due to hypermethylation, a common
225 oncogenic event in PCa. Perhaps more importantly, SFRP2
methylation in combination with other epigenetic markers was
suggested as a useful biomarker in PCa.[26]
Phosphatase and tensin homolog 
The phosphatase and tensin homolog (PTEN) is a tumor sup-
230 pressor protein, responsible for the dephosphorylation of lipid-
signaling intermediates and deactivation of PI3K signaling, thus
controlling cell growth and proliferation. PI3K signaling plays a
pivotal role in PCa cell survival and progression to the androgen
refractory state. Loss of the tumor suppressor PTEN and
235subsequent activation of AKT1 enhances prostate tumor growth
and bone metastasis through stimulating the CXCL12/CXCR4
signaling axis.[27] Thus, ablation of PTEN expression is defi-
nitely a critical factor in progression toward metastatic disease
and has been suggested to constitute an early prognostic bio-
240marker for PCa metastasis.[28] The strong association of aber-
rant PI3K signaling with metastasis and poor survival of PCa
patients highlights the enormous putative impact of inhibition
of the PI3K signaling pathway on PCa patient survival.[29] For
instance, AKT1 inhibitors could be employed as anticancer
245agents to counteract expansion of bone metastases in PCa.
Homozygous deletion of the PTEN gene and loss of hetero-
zygosity followed by a second inactivation event are frequent in
malignant prostate tumors. Moreover, PTEN haploinsufficiency
is likely to contribute in the transition from preneoplastic pro-
250static intra epithelial neoplasia  to PCa.[30] Interphase FISH
analysis of PTEN in histologic sections of malignant prostate
neoplasms revealed that genomic loss of PTEN is indicative of
advanced-stage disease at surgery and a poor prognosticator,
predicting shorter time intervals to biochemical recurrence of
255the disease.[31] Furthermore, its combination with copy num-
ber alterations of other genes such as allelic gain of MYC is
increasingly prognostic for relapse.[32] A previous effort to
genetically distinguish between PCa patients with local risk
and those with systemic risk, based on the application of
260array-based comparative genomic hybridization on prostate tis-
sues and lymph node metastases after radical prostatectomy,
clearly demonstrated that genomic losses on chromosome 10q
(PTEN) and gains on 8q (MYC) were associated with locally
aggressive and metastatic disease.[33] Stratification of PCa
265patients based on the copy number alterations of specific genes
within pre treatment biopsies may improve the use of systemic
therapies to target subclinical metastases or locally recurrent
disease and improve clinical outcomes.
Several studies have shown that PTEN genomic deletion is
270associated with decreased PTEN protein expression, as assessed
by IHC AQ7, both in localized and metastatic cancer. In fact, IHC-
determined PTEN protein loss, assessed as a dichotomous vari-
able, was highly reproducible and strongly associated with
adverse clinicopathological features such as high Gleason score
275and advanced pathologic stage. Interestingly, PTEN protein loss
was found occasionally in the absence of apparent genomic loss,
as well.[34] In particular, loss of PTEN protein expression at the
time of biopsy predicts time to development of metastasis, PCa-
specific mortality, castration-resistant PCa and response to
280androgen deprivation therapy after radical prostatectomy.[35]
Moreover, in patients with conservatively managed, localized
PCa, absence of PTEN protein adds prognostic value to the
Gleason score, PSA, Ki-67 and tumor extent.[36] Especially in
patients with clinically localized PCa treated by prostatectomy,
285negative PTEN expression status is a predictor of increased risk
of recurrence, independent of known clinicopathological para-
meters.[37] These findings support the validity of IHC to
interrogate PTEN expression status in clinical prostate speci-
mens and suggest its application in large multicenter studies,
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290 clinical trials, and even perhaps in clinical routine as an early
marker of aggressive PCa.
Transforming growth factor beta isoforms
Transforming growth factor beta (TGF-β) is an important
regulator of the prostate physiology. In the normal prostate,
295 this secreted pleiotropic protein controls cell growth, prolifera-
tion, differentiation, and apoptosis. TGF-β is also a potent
immunosuppressor, secreted by cells of the immune system.
[38] When activated, this ligand binds to the type II receptor
(TGF-βRII), which in turn recruits type I receptor (TGF-βRI).
300 Subsequently, the activated TGF-βRI phosphorylates its down-
stream targets, the members of the SMAD family of signal
transducers, thus mediating SMAD signaling. Besides that,
TGF-β can induce other non-SMAD signaling pathways,
including the MAPK pathway. On the other hand, perturbation
305 of TGF-β signaling is related to autoimmunity, inflammation
and cancer.[39]
Three distinct isoforms of TGF-β are currently known: TGF-
β1, TGF-β2 and TGF-β3. TGF-β1 constitutes an important
regulator of PCa pathobiology. Being highly expressed in PCa
310 cells, TGF-β1 facilitates tumor growth and metastasis, both by
promoting angiogenesis and by counteracting immune response
directed against tumor cells. Moreover, PCa-derived TGF-β1 is
likely to induce the expression of DNMTs in PCa, resulting in
methylation of the TGFBR1 and TGFBR2 genes.[40] Thus, by
315 gradually losing their TGF-β receptors, PCa cells become resis-
tant to the antiproliferative and proapoptotic effects of TGF-β1.
The loss of TGF-βRI and TGF-βRII may also account for the
ability of some malignant prostate neoplasms to avoid castra-
tion-induced apoptosis. Accordingly, high TGF-β1 protein
320 levels accompanied by loss of TGFβRII expression have been
associated with angiogenesis, metastasis and poor clinical out-
come of PCa patients.[41] For patients subjected to radical
prostatectomy, elevated preoperative plasma TGF-β1 concentra-
tion is associated with positive regional lymph nodes, presumed
325 occult metastases at the time of primary treatment and disease
progression,[42] while TGF-β1 overexpression by prostate
tumor cells is associated with pathological features of the
tumor and biochemical progression.[41] Additionally, TGF-β1
is overexpressed in metastatic primary PCa, compared to non-
330  metastatic PCa.[43]
With regard to TGF-β2, this TGF-β isoform seems to con-
stitutively activate NF-κB in PC-3 cells, thus blocking apoptosis
and leading to sustained tumor cell survival. Since TGFB2
silencing via specific siRNAs was shown to trigger PC-3 cell
335 death, TGF-β2 could be exploited as a potential therapeutic
target to inhibit growth of tumor cells or to sensitize them to
cytotoxic drugs.[44]
Interleukin-6 
Interleukin-6 (IL-6) is a cytokine playing a pivotal role in
340 regulation of the immune system, hematopoiesis, acute phase
responses, cell proliferation and differentiation. IL-6 exerts its
pleiotropic action through binding its receptor (IL6R) and
subsequently activating JAK/STAT and MAPK signaling path-
ways. Besides regulating immune and inflammatory responses,
345IL-6 regulates VEGFA expression and stimulates the growth of
cancer cells, including PCa cells. Because of its overexpression in
PCa tissues at early disease stage and its implication in autocrine
and paracrine loops that trigger neuroendocrine differentiation
in prostate, IL-6 has been in the center of PCa research.[45]
350Not surprisingly, preoperative serum levels of IL-6 and its
soluble receptor, sIL6R [official symbol: IL6ST (interleukin 6
signal transducer)], were found to be significantly associated
with the extent of the disease, tumor volume, prostatectomy
Gleason score, positive lymph nodes, and clinical stage.[42,46]
355Serum IL-6 level is also related to clinical stage and constitutes a
significant prognostic factor in PCa.[47] In patients with clini-
cally localized PCa and thereby undergoing radical prostatect-
omy, the preoperative levels of IL-6 and sIL6R in plasma
independently predict biochemical progression following sur-
360gery, most probably due to occult metastases at the time of
surgery. In support of this conclusion, plasma IL-6 and IL-6sR
levels were found to be dramatically higher in PCa patients with
bone metastases.[42] More interestingly, plasma IL-6 concentra-
tion retained its high prognostic significance in the group of
365patients with hormone-refractory, metastatic PCa.[48] These
findings support the notion that IL-6 concentration in serum
or plasma could be incorporated into multiparametric prognos-
tic models. IL-6 has also been suggested as a biomarker for
docetaxel response monitoring, as dramatic reduction in IL-6
370levels early after treatment onset are indicative of clinical
response of PCa patients to this drug.[49] Nevertheless, further
studies are needed to elucidate the potential clinical significance
of IL-6 inhibition in human PCa.
Chromogranin A 
375Chromogranin A (CHGA), also known as parathyroid secretory
protein 1, belongs to the chromogranin/secretogranin family of
neuroendocrine secretory proteins. CHGA, a compound found
in the secretory vesicles of neurons and endocrine cells, is a
precursor to several functional peptides, including vasostatins 1
380and 2, pancreastatin, parastatin, catestatin, and chromofungin.
The first four of these biologically active peptides act as auto-
crine or paracrine negative modulators of the neuroendocrine
system, while the other two peptides have antimicrobial
properties.
385Elevated expression of CHGA is indicative of neuroendocrine
malignancies, including PCa with neuroendocrine differentia-
tion. Several studies have shown that CHGA may be a promis-
ing prognostic biomarker in PCa. IHC-assessed CHGA
expression in prostate tissue is associated with Gleason score.
390[50] Furthermore, CHGA expression in PCa needle biopsies at
the time of diagnosis constitutes an independent prognostic
factor of survival.[51] It also correlates with circulating levels
of CHGA, particularly in PCa patients with metastatic disease.
[52] High CHGA concentration in plasma is very common in
395patients with hormone-refractory PCa and, more importantly,
constitutes a predictor of poor prognosis, especially in patients
4 Expert Rev. Mol. Diagn. 00(00), (2015)
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with metastatic castration-resistant PCa treated with abiraterone
or enzalutamide.[53,54] In PCa patients with non metastatic
carcinoma, elevated circulating levels of CHGA predict bio-
400 chemical progression and, when combined with PSA, effectively
predict poor survival after endocrine therapy.[55] In accordance
with these findings, Krauss et al. have recently shown that
neuroendocrine differentiation, as indirectly assessed by
CHGA immunostaining, is a predictor of distant metastases
405 and disease-specific survival in newly diagnosed PCa patients
treated with definitive radiotherapy.[56] Therefore, it appears
that CHGA is a very promising blood-based biomarker in PCa
deserving more clinical evaluation.
Erythroblast transformation-specific family members
410 The members of the erythroblast transformation-specific (ETS)
family of transcription factors are key regulators of embryonic
development, cell proliferation, differentiation, angiogenesis,
inflammation and apoptosis. Modulations in the ETS transcrip-
tion factor activity in PPC-1 cells exert an inhibitory effect on
415 anchorage-independent growth, survival and invasiveness of
these prostate tumor cells.[57] Interestingly, recurrent gene
fusions involving the 5ʹ-untranslated region ( UTR) of the
androgen-regulated transmembrane serine protease 2
(TMPRSS2) gene and the ETS family genes ERG, ETV1,
420 ETV4, ETV5 and FLI1 have been identified in most PCa
cases.[58] From a mechanistic point of view, ERG plays a
major role in PCa progression, as it activates the MYC oncogene
and represses prostate epithelial differentiation genes such as
PSA and prostein (solute carrier family 45 member 3 
425 [SLC45A3]), thus abolishing prostate epithelial differentiation.
[59] The same transcription factor enhances also prostaglandin-
mediated signaling, which favors tumor progression.[60]
In fact, the detection of transcripts produced from the
TMPRSS2:ERG chimeric gene in surgically treated PCa patients
430 was initially shown to strongly predict disease recurrence, inde-
pendently of grade, stage, and serum PSA levels.[61] In contrast
with this finding, Saramaki et al. concluded that the TMPRSS2:
ERG rearrangement in primary prostate tumors is an indepen-
dent predictor of longer progression-free survival and favorable
435 outcome in PCa patients treated by prostatectomy. Moreover,
this chimeric gene was not associated with Gleason score,
pathological tumor extent (pT), diagnostic PSA levels or cell
proliferation activity in prostatectomy samples nor with the AR
gene amplification in hormone-refractory malignant neoplasms.
440 [62] This prognostic controversy could be partly explained by
the fact that ERG expression is AR-dependent and hence pros-
tate tumors overexpressing ERG due to TMPRSS2:ERG fusion
are likely to progress in an androgen-rich environment but
respond better to androgen suppression.[63] On the other
445 hand, there are also studies implying no prognostic significance
for this chimeric gene.[64]
Besides the TMPRSS2 gene, ETS family members have many
other 5′-fusion partners that are occasionally present in prostate
tumors, including SLC45A3, OR51E2, ERVK-17, UBTF,
450 NDRG1, and the strongly expressed housekeeping gene
HNRPA2B1.[58] Nevertheless, the prognostic potential of chi-
meric genes containing ETS family members and their afore-
mentioned fusion partners has not been extensively studied,
so far.
455α-Methylacyl-CoA racemase 
α-Methylacyl-CoA racemase (AMACR) is an enzyme regulating
the entry of branched-chain lipids into the peroxisomal and
mitochondrial β-oxidation pathways. AMACR is significantly
upregulated in PCa, compared to BPH and normal prostate, as
460shown by a meta-analysis of DNA microarray data.[65] Besides
its high diagnostic value in PCa due to its high sensitivity and
specificity, AMACR expression seems to be an important favor-
able prognostic biomarker in this malignancy. In more detail,
low AMACR expression in patients with localized PCa is asso-
465ciated with an increased rate of biochemical recurrence and
PCa-specific death.[66] However, additional studies are needed
to fully uncover the prognostic significance of AMACR in PCa.
Endoglin 
Endoglin (ENG) is a major homodimeric transmembrane gly-
470coprotein of the vascular endothelium, mainly expressed in
proliferating endothelial cells. As a component of the TGF-β
receptor complex, ENG binds to TGF-β1 and TGF-β3 with
high affinity. The presence of ENG is a feature of newly formed
tumor vessels, rendering this protein a biomarker of ongoing
475angiogenesis in prostate.[67] In patients with organ-confined
PCa treated with radical prostatectomy and subsequent neoad-
juvant hormonal therapy, high tumor microvessel density – as
evaluated by elevated ENG expression – constitutes a significant
and independent predictor of biochemical recurrence.[68]
480Positive ENG immunostaining was also associated with high
Gleason score, nodal metastases and advanced disease stage,
suggesting a putative prognostic role for overall survival.[67]
Non coding genes as molecular biomarkers in PCa
Prostate cancer associated 3 
485Prostate cancer associated 3 (PCA3) is a long non coding RNA,
synthesized almost exclusively in the prostate and overex-
pressed in PCa tissues and metastases, compared with BPH
tissue. PCA3 is implicated in the control of PCa cell survival,
partly through modulating AR signaling, and exerts its main
490action in the nuclei and microsomal cell fractions.[69]
Although castration-resistant prostate tumors lack PCA3
expression, the question whether disease progression per se
affects PCA3 expression remains unanswered. PCA3 is useful
as a biomarker in PCa as it is able to stratify patients based on
495prostatectomy tumor volume and Gleason score and may thus
have clinical applicability in distinguishing those having low
volume/low grade PCa and selecting patients eligible to
undergo active surveillance and nerve-sparing surgery.[70]
Nonetheless, the association between PCA3 score and clinico-
500pathological factors is controversial, as several studies have
failed so far to demonstrate such associations or any prognostic
significance for this long non-coding RNA in PCa.[71]
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Therefore, in spite of the fact that the clinical usefulness of the
PCA3 test for the detection of PCa and the possible decrease of
505 unnecessary biopsies has been well established,[72] additional
studies are required to investigate the potential of PCA3
expression as a prognostic biomarker in PCa.
MicroRNAs 
MicroRNAs (miRNAs) are small non coding RNAs of about
510 19–24 nucleotides that regulate protein-coding gene expression
by inhibiting translation and/or destabilizing targeted tran-
scripts. miRNAs recognize target sites in the 3' - UTR of
mRNAs and probably in the 5 '-UTR through imperfect base
pairing. miRNAs play a very important role in prostate physiol-
515 ogy, acting as oncogenes or tumor suppressors, whereas mod-
ulations in their expression contribute to prostate
carcinogenesis.[73] Since miRNAs serve as phenotypic signa-
tures of different cancers, they appear as potential diagnostic,
prognostic and therapeutic tools.
520 The first large-scale study investigating the diagnostic and
prognostic implications of microRNA profiling in PCa was
reported in 2010. Among the 15 miRNAs (miR-16, miR-31,
miR-96, miR-125b, miR-145, miR-149, miR-181b, miR-182,
miR-182*, miR-183, miR-184, miR-205, miR-221, miR-222 
525 and miR-375) that were differentially expressed between can-
cerous and normal prostate tissue, miR-31, miR-96 and miR-
205 were the only ones to be associated with Gleason score,
while miR-125b, miR-205 and miR-222 were associated with
tumor staging.[74] One of the most promising prognostic
530 biomarkers for PCa is the prostate-specific miR-221, an
oncomiR that regulates proliferation, apoptosis and invasion
of PCa cells by inhibiting IRF2 and SOCS3.[75] Low miR-
221 expression was shown to be associated with clinicopatho-
logical factors, including the Gleason score and the clinical
535 recurrence.[76] In fact, PCa patients with localized tumors
expressing miR-221 at low levels have a greater risk for recur-
rence after surgery. Progressive loss of miR-221 expression has
been designated as a hallmark of metastasis, which explains the
high prognostic significance of miR-221, highlighted by inde-
540 pendent studies.[75,76]
Another miRNA that seems to be highly significant in terms
of prognostic capability is miR-145. This tumor suppressor
miRNA regulates androgen-dependent prostate cell growth by
suppressing AR, in vitro. Low miR-145 expression in PCa was
545 associated with higher Gleason score, presence of metastases,
advanced clinical stage and androgen deprivation therapy
response. In accordance with these findings, miR-145 was a
reliable predictor of biochemical relapse and poor DFS in PCa
patients.[77] Similarly, loss of miR-378 expression was asso-
550 ciated with aggressive PCa and shown to predict short-term
relapse of PCa patients despite any treatment.[78]
Besides the aforementioned miRNAs, there are several others
that have been proposed as putative prognostic biomarkers in
PCa; one of them is miR-224. This PCa-related miRNA was
555 shown to regulate the expression of calcium/calmodulin-depen-
dent protein kinase 2 (CAMKK2) and apelin (APLN), a peptide
that functions as an endogenous ligand for the G protein-
coupled receptor APJ and that hence activates distinct tissue-
specific signaling pathways.[79,80] Defects of the miR-224/
560APLN axis are considered to promote prostate carcinogenesis
and aggressive progression of the disease. Thus, low miR-224
levels were significantly associated with advanced clinical stage
and metastasis in PCa.[80] Nonetheless, the favorable prognos-
tic role of miR-224 expression in PCa was not superior to the
565prognostic significance of conventional biomarkers that are used
for prognostic purposes.
Expert commentary
The currently used staging system and other prognostic factors
have inherent limitations and usually lead to overtreatment of
570PCa, especially in men of 66 years and older with a limited life
expectancy. It is, therefore, evident that more “objective” bio-
markers are needed to ameliorate the accuracy of patient prog-
nosis and subsequent treatment decision making. Undoubtedly,
the discovery of novel molecular biomarkers and their establish-
575ment in clinical practice could bridge this gap between predic-
tion of outcome and true patient outcome.
The clinical interest of the aforementioned molecules as
potential biomarkers for prognosis and monitoring of treatment
efficacy in PCa has been extensively studied during the last
580decades. The elucidation of the biochemical pathways involved
in prostate carcinogenesis, tumor progression and metastasis are
expected to assist the discovery of novel biomarkers in PCa and
the development of more personalized treatment with increased
possibilities for curative success. Additionally, some of the mole-
585cular biomarkers presented in this review could hold prognostic
significance, alone or in panels, in particular subtypes of PCa.
The frequently observed modulations in protein and/or mRNA
expression in malignant prostate tumors compared to benign
hyperplasia and/or normal specimens originating from the
590prostate suggest the notion that some of these novel promising
biomarkers deserve further validation in large cohorts of PCa
patients.
Five-year view
The emerging potential of several molecules as molecular tumor
595biomarkers – along with the need for more reliable prognosis
and prediction of therapy response – will lead to the develop-
ment of multivariate panels of biomarkers. Moreover, the use of
high-throughput quantitative methodologies including next-
generation sequencing will soon uncover the prognostic ability
600of several mRNAs, long non coding RNAs and miRNAs that
have not been studied yet as standalone biomarkers. The first
efforts have already proven to be fruitful; for instance, a few
long intergenic non coding RNAs have just emerged as candidate
biomarkers for PCa diagnosis and prognosis.[81–83] However,
605there is still much work to be done.
Besides miRNAs, there are several other classes of small
non coding RNAs that are more intensively studied during the
last years and that are expected to add clinical significance to the
existing PCa biomarkers. Such molecules include stress-induced
6 Expert Rev. Mol. Diagn. 00(00), (2015)
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610 tRNA fragments (tRFs, also known as tiRNAs), small nuclear
RNA fragments and small nucleolar RNA fragments. These tiny
non coding RNAs that have very recently emerged as regulatory
RNAs are present at high levels in the prostate tissue as well as
in blood and urine, either as circulating or enclosed in exo-
615 somes. Interestingly, some of them have already been shown to
be heavily implicated in metastasis and other cancer-related
processes. Moreover, extracellular vesicles such as PCa cellular
fragments could also serve as a fluid biopsy for PCa. In parallel,
the further unraveling of the functions of novel RNAs will
620 significantly contribute to the clarification of the genetic and
molecular basis of PCa.
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